Editor’s note: Inheritance is to protect the roots, without inheritance, the original source cannot be cleaned up; innovation is for improvement, without innovation, it is impossible to keep pace with the times. The “14th Five-Year Plan” and the outline of the long-term goals for 2035 put forward that it is necessary to promote the inheritance and innovation of traditional Chinese medicine, adhere to the equal emphasis and complementary advantages of traditional Chinese medicine and western medicine, and vigorously develop the cause of traditional Chinese medicine. Therefore, it can be seen that under the guidance and strong support of the state, the great development of traditional Chinese medicine is at the right time. There is no limit to the vastness, sailing but the trade winds. As a leading enterprise in the scientific and technological innovation of traditional Chinese medicine, Yiling Pharmaceutical adheres to the principle of “inheriting the ancients and innovating without leaving the ancestry”, combining traditional Chinese medicine with the crystallization of the wisdom of the Chinese nation for thousands of years with modern technology, and constantly innovating new products suitable for contemporary people. The traditional Chinese medicine makes the “Chinese prescription” glow with lasting vitality. Looking back 30 years, how did Yiling Pharmaceutical create a new pattern of inheritance, innovation and development of traditional Chinese medicine? How should we contribute to the construction of a healthy China? Please follow our footsteps and walk into Yiling Pharmaceutical to learn about its unique “secret recipe” for the development of innovative Chinese medicine. Today, the second report in the series “Innovative “Breakthrough” Brings New Vitality to Ancient Chinese Medicine” is launched:
Hou Yunlong, deputy director of the New Drug Research and Development Center of the Chinese Academy of Medicine. Photo courtesy of Yiling Pharmaceutical
Hou Yunlong has been very busy recently. In the early morning, he changed into a white coat as usual, walked into the spacious and bright laboratory, and began to operate the precise instruments in front of him. Soon, a live image of a mouse appeared on the screen, and Hou Yunlong began to observe it carefully. By analyzing these cell structures, the observation and evaluation of the aging-related morphology and microcirculation structure of small animals can be completed.
Here is the anti-aging research and development platform of Yiling Pharmaceutical, and Hou Yunlong is the platform leader. Aging and anti-aging is a common topic. The idea that seems to be difficult to break through is a “highlight” worthy of research in Yiling Pharmaceutical.
“As the problem of social aging becomes more and more prominent, Yiling Pharmaceutical has taken the lead in launching the construction of an anti-aging platform. Guided by the theory of collateral diseases, we provide new drug options for delaying premature aging, and fill the basis for There is no drug treatment for systemic diseases with pro-aging factors.” Speaking of the original intention of the platform, Hou Yunlong was very excited, “At present, four SCI-indexed articles have been published on the staged results of research on systemic aging.”
It is understood that Yiling Pharmaceutical’s anti-aging drug research and development platform has a total area of 1,200 square meters and nearly 200 sets of equipment. Regarding the scientific research investment of the platform, Hou Yunlong touched these instruments one by one like a baby, and then spread out his palm mysteriously, “The total value of these is more than 50 million yuan. And in the next two years, our company will continue to invest in this platform.”
“The next step of the platform will continue to carry out work from three aspects: theoretical research, experimental research, and clinical research. It will target multiple anti-aging targets such as aging cell clearance, stem cell maintenance, immune system regulation, and metabolic pathway regulation. , to carry out the research and development of innovative drugs for aging-related diseases.” Hou Yunlong said.
In the past 30 years since its establishment, Yiling Pharmaceutical has continuously accelerated the pace of scientific research and innovation. It has increased year by year. In 2021, Yiling Pharmaceutical will invest 838 million yuan in R&D, accounting for 8.28% of its operating income, and the proportion of R&D revenue has exceeded 8% for four consecutive years.
Investment in scientific research should not only focus on “things”, but also “people”. The reason why Yiling Pharmaceutical can continuously export innovative patented drugs depends on its perfect scientific research platform and high-precision talents. It is understood that Hebei Yiling Medical Research Institute is the State Key Laboratory of Collateral Disease Research and Innovative Traditional Chinese Medicine. This national scientific research platform has presided over the national key research and development plan, “973”, “863” and other national, provincial and ministerial levels. There are more than 90 subjects, and more than 1,000 R&D talents such as Ph.D. and master students and returnees have been trained and introduced.
Not only an anti-aging platform, but also for scientific research achievements, Yiling Pharmaceutical focuses on high-quality transformation, forming a unique scientific and technological core competitiveness. Focusing on six major diseases with high incidence and large market dosage, such as cardiovascular and cerebrovascular diseases, diabetes, respiratory diseases, tumors, nervous system diseases, and urinary system diseases, 13 patented traditional Chinese medicines with independent intellectual property rights have been developed and marketed, and 8 Included in the National Medical Insurance Catalog, and 5 in the National Essential Drugs Catalog; created the eight-character health culture of “draining collaterals, nourishing essence, moving body, and calming the mind”, and proposed a new concept of health management that “the body needs to be managed, and the health needs to be managed”; We have developed a series of products for dredging collaterals, healthy heart and brain, anti-aging, anti-aging and immunity-enhancing products, dynamic anti-fatigue and joint care products, which have the functions of regulating sugar, lowering blood pressure, reducing lipids and losing weight, laxative, detoxification, and regulating internal organs. A series of products for calming the mind, helping sleep and improving mood, covering a number of sub-health and chronic disease fields…
In 2019, the project “Construction of TCM Context Theory and Its Guidance for Prevention and Treatment of Microvascular Diseases” won the first prize of National Science and Technology Progress Award. This is the sixth time Yiling Pharmaceutical has won the National Science and Technology Award. When the news came, everyone including the R&D team and decision makers couldn’t hide their excitement. But they know that the pace of scientific research and innovation of Yiling Pharmaceutical is still moving forward, and the pace is getting bigger and faster, and there is still a long way to go.